In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGAA's Hostile Bid Catalyzes Bayer-Schering Combo

Executive Summary

In March 2006, Bayer AG's €16.3 billion ($19.6 billion) cash offer for Schering trumped compatriot Merck KGAA's unsolicited €14.6 billion takeover bid for the specialist pharma marketer. The offers to acquire Schering put a spotlight on Europe's mid-sized players, most of which are either on the acquisition trail or putting up For Sale signs in front of corporate headquarters.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts